Dave Williamson
XMFGreenwave4
The Motley Fool's Healthcare Analyst, I specialize in Pharma, Biotech, and how the ACA (Obamacare) is changing the business of healthcare in America. Follow me on Twitter for breaking stock news, policy thoughts, and misc musings...
Recent Articles by Dave Williamson

Apr 7, 2017
by Dave Williamson
2 Biotechs Get the FDA's Thumbs-Up

Apr 7, 2017
by Dave Williamson
A Big Drug Roundup for Big Pharma

Apr 7, 2017
by Dave Williamson
MAPping Out an FDA Approval

Apr 7, 2017
by Dave Williamson
This Spinoff Just Got More Interesting

Apr 7, 2017
by Dave Williamson
Is FDA Approval in the Bag for NPS?

Apr 7, 2017
by Dave Williamson
Another Day, Another Biotech Dilution

Apr 7, 2017
by Dave Williamson
4 Biotech Stocks Finish Big

Apr 7, 2017
by Dave Williamson
Barclays Goes to the Hospital

Apr 7, 2017
by Dave Williamson
Why Is Eli Lilly Climbing?

Apr 7, 2017
by Dave Williamson
4 Headline Moving Health-Care Stocks

Apr 7, 2017
by Dave Williamson
A Big Pharma's Big Delusion?

Apr 7, 2017
by Dave Williamson
This Falling Scalpel Could Cut You

Apr 7, 2017
by Dave Williamson
The Obesity War Escalates
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.